Vitamin B, E health claims
This article was originally published in The Tan Sheet
Executive Summary
Stay of litigation in Whitaker v. Shalala extended until Feb. 9 as FDA continues to review proposed vitamin E/heart disease claim and the parties negotiate language for a qualified B vitamin/vascular disease claim. Plaintiff dietary supplement marketers and developers continue to insist a CDC statement recognizing elevated plasma homocysteine as an independent risk factor for vascular disease should be included in any B vitamin claim. Previous litigation stay expired Jan. 12 (1"The Tan Sheet" Dec. 18, 2000, p. 7)
You may also be interested in...
Vitamin B Health Claim Omits CDC Homocysteine Findings, Plaintiffs Say
FDA should amend its vitamin B qualified health claim to reflect a Centers for Disease Control & Prevention statement recognizing elevated plasma homocysteine as a vascular disease risk factor, plaintiffs in the Whitaker v. Shalala case assert.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands